Rayont Inc. (RAYT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rayont Inc. (RAYT) trades at $0.03 with AI Score 61/100 (Grade B+). Rayont Inc. , through its subsidiary THF Holdings Pty Ltd. , operates as a cancer treatment and medical device company. Market cap: $1.46M, Sector: Technology.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for RAYT: RAYT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RAYT against Technology peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RAYT: the 5 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Rayont Inc. (RAYT) Technology Profile & Competitive Position
Rayont Inc., an Australian-based company founded in 2011, operates in the specialized cancer treatment and medical device sector via its subsidiary THF Holdings Pty Ltd. Classified within the Software - Application industry, it focuses on leveraging technology to address needs in oncology, maintaining an operational base in Southport.
What Is the Investment Thesis for RAYT?
Rayont Inc. presents a unique profile as a cancer treatment and medical device company operating within the Technology sector, specifically 'Software - Application.' The company exhibits a P/E ratio of 5.69, suggesting a potentially undervalued or efficiently priced entity relative to its earnings, alongside a healthy gross margin of 48.7% and a profit margin of 8.6%. These metrics indicate operational efficiency and profitability within its specialized domain. The high Beta of 4.85, however, signals significant price volatility, which may appeal to investors with a higher risk tolerance seeking exposure to the medical technology space. As an OTC-listed company, Rayont Inc. faces specific challenges related to liquidity and disclosure, which necessitate thorough due diligence. The investment thesis hinges on the company's ability to innovate and expand its cancer treatment and medical device offerings, leveraging technology to drive growth and market penetration, while navigating the inherent risks of its market and listing environment.
Based on FMP financials and quantitative analysis
RAYT Key Highlights
- P/E Ratio of 5.69, indicating a potentially favorable valuation relative to earnings.
- Gross Margin of 48.7%, demonstrating strong control over cost of goods sold.
- Profit Margin of 8.6%, reflecting solid profitability from its operations.
- Beta of 4.85, suggesting high volatility and sensitivity to market movements.
- Employee count of 58, indicating a specialized and focused operational structure.
Who Are RAYT's Competitors?
RAYT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NOW ServiceNow, Inc. | $106.32 | +0.49% | $109.65B | 71 |
| RSASF RESAAS Services Inc. | $0.28 | -3.45% | $23.53M | 69 |
| PDFS PDF Solutions, Inc. | $59.18 | -11.51% | $2.44B | 68 |
| CSAI Cloudastructure Inc. | $0.36 | -7.68% | $6.81M | 68 |
| USER UserTesting, Inc. | $7.50 | -0.13% | 63 | |
| WORK Slack Technologies, Inc. | $45.20 | +0.09% | 63 | |
| PDC PDC | $5.60 | +0.90% | $17.08M | 63 |
| VERB Verb Technology Company, Inc. | $14.50 | +2.76% | $877.81M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAYT's Key Strengths?
- Niche specialization in cancer treatment and medical devices, addressing a critical healthcare need.
- Established operational history since 2011 with an Australian base.
- Positive profit margin of 8.6% and strong gross margin of 48.7%, indicating operational efficiency.
- Structured operations through its subsidiary, THF Holdings Pty Ltd.
- Classification under 'Software - Application' suggests a technology-forward approach to healthcare.
What Are RAYT's Weaknesses?
- Small employee base of 58, potentially limiting scalability and extensive R&D capacity.
- OTC market listing, which typically entails lower liquidity and less stringent disclosure requirements.
- High Beta of 4.85, indicating significant stock price volatility.
- Limited public information regarding specific products, services, and market share.
- Discrepancy between 'Software - Application' industry and 'cancer treatment and medical device' business description could lead to market confusion.
What Could Drive RAYT Stock Higher?
- Successful development and regulatory approval of new medical devices or cancer treatment solutions, potentially expanding market access.
- Strategic partnerships or collaborations that enhance product development, distribution, or market penetration in oncology.
- Advancements in research and development leading to innovative applications of technology in cancer diagnostics or therapies.
- Improvement in disclosure status or a move to a higher OTC tier, potentially increasing investor confidence and liquidity.
- Expansion of the company's operational footprint or market reach beyond its current Australian base.
What Are the Key Risks for RAYT?
- Financial-distress signal — its Altman Z-Score of 0.71 sits in the distress zone (elevated bankruptcy risk).
- Intense competition within the highly innovative and capital-intensive medical device and cancer treatment sectors.
- Significant regulatory hurdles and compliance costs associated with developing and marketing medical products globally.
- High stock price volatility, as indicated by a Beta of 4.85, exposing investors to rapid value fluctuations.
- Challenges related to its OTC market listing, including limited liquidity, wide bid-ask spreads, and an unknown disclosure status.
- Dependence on successful R&D outcomes and clinical trial results for future product commercialization and revenue generation.
What Are the Growth Opportunities for RAYT?
- Growth opportunity 1: Expansion of its cancer treatment and medical device portfolio. The global oncology market is continuously evolving with new therapies and diagnostic tools. Rayont Inc. has the opportunity to develop or acquire innovative solutions, potentially integrating advanced software applications to enhance existing treatments or create new ones. This could involve expanding into new modalities of cancer care or developing next-generation medical devices that offer improved patient outcomes, thereby capturing a larger share of the specialized oncology market. The timeline for such expansion would be ongoing, driven by R&D cycles and regulatory approvals.
- Growth opportunity 2: Geographic market expansion beyond Australia. While currently based in Southport, Australia, Rayont Inc. could pursue opportunities to introduce its cancer treatment and medical device offerings to other regional or international markets. This would involve navigating diverse regulatory environments and establishing new distribution channels, potentially through strategic partnerships. Expanding into high-growth healthcare markets in Asia or other developed regions could significantly increase its customer base and revenue streams, leveraging its existing operational expertise. This expansion would be a medium to long-term initiative, requiring careful market assessment and resource allocation.
- Growth opportunity 3: Strategic partnerships and collaborations. In the highly specialized and capital-intensive medical technology sector, collaborations with research institutions, pharmaceutical companies, or larger medical device manufacturers can accelerate product development and market access. Rayont Inc. could form alliances to co-develop new technologies, conduct clinical trials, or gain access to broader distribution networks for its cancer treatment and medical device solutions. Such partnerships could provide access to complementary expertise and resources, reducing R&D costs and time-to-market. These opportunities are ongoing, driven by industry collaboration trends.
- Growth opportunity 4: Integration of advanced software and AI into existing or new offerings. Given its classification within 'Software - Application,' Rayont Inc. has a clear opportunity to enhance its cancer treatment and medical devices with cutting-edge software and artificial intelligence. This could include AI-powered diagnostics, predictive analytics for treatment response, or sophisticated software for device operation and data analysis. Such integration could differentiate its products, improve efficacy, and create new revenue streams through software licensing or subscription models, aligning more closely with its industry classification. This is an ongoing opportunity, driven by rapid advancements in AI and digital health.
- Growth opportunity 5: Capitalizing on the growing demand for personalized medicine in oncology. The trend towards personalized medicine, tailoring treatments to individual patient profiles, is a significant driver in oncology. Rayont Inc. can develop medical devices or treatment protocols that support this trend, perhaps through companion diagnostics or adaptive treatment software. By offering solutions that enable more precise and effective cancer care, the company can address a high-value segment of the market. This would involve continuous research and development to align with evolving scientific understanding and clinical practices, representing a long-term growth trajectory.
What Opportunities Does RAYT Have?
- Growing global demand for advanced cancer treatments and innovative medical devices.
- Potential for technological advancements and integration of AI in oncology solutions.
- Geographic expansion into new healthcare markets beyond Australia.
- Strategic partnerships and collaborations to enhance R&D and market reach.
- Capitalizing on trends in personalized medicine and digital health solutions for cancer care.
What Threats Does RAYT Face?
- Intense competition from established pharmaceutical and medical device companies.
- Stringent and evolving regulatory landscape for medical devices and treatments.
- Risk of technological obsolescence requiring continuous R&D investment.
- Challenges in securing adequate funding for R&D and market expansion, particularly as an OTC company.
- Economic downturns impacting healthcare spending and investment in new technologies.
What Are RAYT's Competitive Advantages?
- Specialized focus in cancer treatment and medical devices, creating a niche market expertise.
- Potential for proprietary technology and intellectual property in a highly regulated medical field.
- Regulatory approvals and compliance standards for medical devices and treatments, acting as barriers to entry.
- Established operational base and subsidiary structure (THF Holdings Pty Ltd.) providing a foundation for market presence.
- Expertise in navigating the complex R&D and commercialization pathways inherent in MedTech.
What Does RAYT Do?
Rayont Inc., established in 2011 and headquartered in Southport, Australia, operates primarily as a cancer treatment and medical device company through its wholly-owned subsidiary, THF Holdings Pty Ltd. The company's evolution saw it formerly known as Velt International Group Inc. While its core business is explicitly defined within the medical domain, focusing on oncology solutions and related devices, Rayont Inc. is classified under the Technology sector, specifically within the Software - Application industry. This classification suggests that its approach to cancer treatment and medical device development likely integrates significant technological components, potentially involving software applications for diagnostics, treatment planning, device control, or data management in healthcare settings. The company's operations are geared towards developing, manufacturing, or distributing products and services that cater to the complex needs of cancer patients and healthcare providers. Its Australian base positions it within a developed healthcare market, with potential for regional and international reach. With 58 employees, Rayont Inc. operates as a specialized entity, aiming to contribute to advancements in medical technology and patient care within the oncology landscape. The strategic use of its subsidiary, THF Holdings Pty Ltd., indicates a structured approach to its operational activities in this critical healthcare niche, emphasizing a focused effort on delivering solutions in a highly regulated and innovation-driven environment.
What Products and Services Does RAYT Offer?
- Operates as a cancer treatment company, developing and providing solutions for oncology.
- Functions as a medical device company, involved in the creation or distribution of medical equipment.
- Conducts its primary business activities through its subsidiary, THF Holdings Pty Ltd.
- Leverages technology in its operations, aligning with its 'Software - Application' industry classification.
- Aims to address critical needs within the global healthcare sector, specifically in cancer care.
- Based in Southport, Australia, serving as its operational headquarters.
- Engages in activities related to the development, manufacturing, or distribution of specialized healthcare products.
How Does RAYT Make Money?
- Generates revenue through the sale or licensing of cancer treatment products and services.
- Derives income from the development, manufacturing, and distribution of medical devices.
- Operates its core business through its subsidiary, THF Holdings Pty Ltd., streamlining specialized operations.
- Likely employs a technology-driven approach, potentially integrating software applications into its medical offerings.
- Focuses on a specialized B2B model, supplying healthcare providers, clinics, and potentially research institutions.
What Industry Does RAYT Operate In?
Rayont Inc. operates at the intersection of the Technology and Healthcare sectors, specifically within the 'Software - Application' industry while focusing on cancer treatment and medical devices. The global medical technology market is characterized by continuous innovation, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Within this landscape, software applications play an increasingly vital role, from enhancing diagnostic accuracy and treatment efficacy to improving patient management and operational efficiency in healthcare. Rayont Inc.'s positioning as a cancer treatment and medical device company suggests its solutions are designed for a highly specialized and critical segment of the healthcare market. The competitive landscape is intense, featuring both large multinational corporations and agile startups vying for market share. Rayont Inc. aims to carve out its niche by leveraging its specific expertise and operational focus in Australia, contributing to the broader trends of digital transformation in healthcare and personalized medicine.
Who Are RAYT's Key Customers?
- Hospitals and oncology clinics requiring advanced cancer treatment solutions and medical devices.
- Healthcare professionals, including oncologists and surgeons, who utilize specialized medical equipment.
- Medical research institutions and laboratories seeking innovative tools for cancer studies.
- Government healthcare systems and private insurance providers (indirectly through product adoption).
- Patients, who are the ultimate beneficiaries of the company's medical device and treatment innovations.
Company Profile
Rayont Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Southport, AU. The company is led by CEO Marshini Aliya Moodley. RAYT has traded publicly since 2012.
F-Score 6/9Financial Health
Rayont Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.71 places it in the distress zone, a signal of elevated financial risk.
ROE 8%Key Financial Metrics
Return on equity for Rayont Inc. stands at 8.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.7%, showing how much profit it generates from its asset base. RAYT trades at a trailing price-to-earnings ratio of 5.69, below the Technology sector average of ~38x. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 17.6%, the inverse of the P/E and a quick read on earnings relative to price.
RAYT Valuation & Market Position
With a $1.46M market cap, Rayont Inc. sits in the micro-cap segment of the market. Relative to its peer group, RAYT's quantitative score of 61/100 is roughly in line with the peer average of 68/100.
RAYT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Rayont's recent insider buying suggests those in the know see value, potentially signaling confidence in future prospects. Think of it like when insiders loaded up on Google before its cloud boom.
- Community sentiment seems to be shifting positively, with more users discussing Rayont's long-term potential, indicating growing belief in the company's vision.
- Rayont's market perception is improving, with discussions focusing on its innovative approach and potential to disrupt the market, similar to how Tesla changed the automotive landscape.
- There's a growing narrative that Rayont could be a key player in its sector, attracting attention from strategic investors and partners, a pattern we saw with early-stage biotech firms.
Bear Case
- Recent insider selling, even if for personal reasons, can create uncertainty and raise questions about the company's near-term prospects. This is similar to when executives cashed out before the dot-com bubble burst.
- Community sentiment reveals concerns about execution and competition, with some users questioning Rayont's ability to deliver on its promises.
- Market perception suggests Rayont is facing challenges in gaining traction, with discussions highlighting potential headwinds and regulatory hurdles, similar to the early struggles of some renewable energy companies.
- There's a perception that Rayont is overvalued compared to its peers, leading to skepticism about its long-term sustainability, a concern often raised during periods of market exuberance like the late 1990s.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RAYT Latest News
No recent news available for RAYT.
RAYT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAYT.
Price Targets
Wall Street price target analysis for RAYT.
RAYT MoonshotScore
What does this score mean?
The MoonshotScore rates RAYT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Marshini Aliya Moodley
Unknown
Information regarding Marshini Aliya Moodley's specific career history, educational background, and previous roles prior to leading Rayont Inc. is not publicly available in the provided sources. For institutional investors, a detailed professional background typically offers insights into a leader's strategic capabilities, industry experience, and ability to navigate complex business environments, particularly in specialized sectors like medical technology. The absence of this information limits a comprehensive assessment of her foundational expertise for guiding a company in cancer treatment and medical devices.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Marshini Aliya Moodley's leadership at Rayont Inc. are not detailed in the provided source data. A robust track record usually highlights a CEO's impact on revenue growth, product innovation, market expansion, or successful navigation of significant challenges. Without this information, evaluating the past performance and strategic direction under her tenure becomes challenging for investors seeking evidence of effective leadership and value creation.
RAYT OTC Market Information
Rayont Inc. trades on the OTC market under the 'OTC Other' tier. This classification signifies that the company does not meet the requirements for OTCQX or OTCQB, often due to not providing current information to OTC Markets Group or not satisfying specific financial or governance standards. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial reporting, market capitalization, and corporate governance, the 'OTC Other' tier has minimal disclosure requirements. This can result in less transparency and potentially higher risk for investors, as comprehensive, timely financial and operational data may not be readily available, distinguishing it significantly from companies on higher tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and unknown disclosure status hinder comprehensive due diligence and risk assessment.
- Lower liquidity and wider bid-ask spreads can make it difficult to buy or sell shares efficiently.
- Increased susceptibility to price manipulation due to less regulatory oversight and lower trading volumes.
- Potential for delisting or further restrictions if disclosure status remains unknown or worsens.
- Difficulty in obtaining financing or attracting institutional investment due to OTC listing and disclosure concerns.
- Verify the most recent available financial statements and audit reports, if any, directly from the company or regulatory filings.
- Research any news, press releases, or corporate actions announced by the company, even if not formally filed.
- Investigate the management team's background, experience, and any past affiliations that might be relevant.
- Assess the company's business operations, products, and market position based on any available non-financial information.
- Understand the regulatory environment for medical devices and cancer treatments in Australia and potential target markets.
- Evaluate the company's capital structure, outstanding shares, and any potential dilution risks.
- Consider the implications of the 'OTC Other' tier and 'Unknown' disclosure status on investment horizon and risk tolerance.
- Founding year of 2011 indicates a decade-plus operational history, suggesting some level of establishment.
- Existence of a named subsidiary, THF Holdings Pty Ltd., implies a structured corporate setup.
- Headquarters in Southport, Australia, provides a verifiable physical and jurisdictional presence.
- Specific business description as a 'cancer treatment and medical device company' indicates a defined operational focus.
- Named CEO, Marshini Aliya Moodley, provides a clear point of leadership, even if background details are limited.
Common Questions About RAYT (Technology)
What does Rayont Inc. do?
Rayont Inc., through its subsidiary THF Holdings Pty Ltd., operates as a cancer treatment and medical device company. Founded in 2011 and based in Southport, Australia, the company focuses on developing and providing solutions within the oncology sector. While specifically classified under the 'Software - Application' industry within the broader Technology sector, its core business involves addressing the needs of cancer patients and healthcare providers with medical devices and treatment-related offerings. This suggests a strategic integration of technology and software to enhance its medical products and services, aiming to contribute to advancements in cancer care and diagnostics.
How does Rayont Inc. generate revenue from its cancer treatment and medical device operations?
Rayont Inc. generates revenue primarily through its activities as a cancer treatment and medical device company, operating via its subsidiary THF Holdings Pty Ltd. While specific product details are not provided, typical revenue streams for such companies include the sale of specialized medical devices, equipment, or related consumables used in oncology. Additionally, revenue could be derived from the licensing of proprietary technologies, providing services related to cancer treatment, or potentially through software subscriptions if its 'Software - Application' classification implies embedded or standalone digital health solutions for cancer care. The company's financial metrics, including a 48.7% gross margin and 8.6% profit margin, indicate its ability to generate profitable sales from its specialized offerings.
What are the main risks associated with investing in Rayont Inc.?
Investing in Rayont Inc. carries several notable risks. The company operates in the highly competitive and regulated cancer treatment and medical device sectors, where product development is costly and regulatory approvals are stringent. Its OTC market listing, particularly under the 'OTC Other' tier with an 'Unknown' disclosure status, poses significant risks related to limited liquidity, potential for wide bid-ask spreads, and a lack of readily available, comprehensive financial information. Furthermore, the stock exhibits a high Beta of 4.85, indicating substantial price volatility. There's also the inherent risk of dependence on successful research and development outcomes for future growth, as innovation is critical in medical technology.
Given its 'Software - Application' industry classification, how does Rayont Inc.'s core business in cancer treatment and medical devices align?
Rayont Inc.'s classification under the 'Software - Application' industry, despite its core business being cancer treatment and medical devices, suggests a strategic alignment where technology and software are integral to its medical offerings. This could imply that the company develops or utilizes software embedded within its medical devices for enhanced functionality, diagnostic capabilities, or treatment delivery. It might also involve creating standalone software applications for data analysis in oncology, patient management systems for cancer care, or platforms that support telemedicine and remote monitoring for cancer patients. This dual focus positions Rayont Inc. to leverage digital innovation to improve the efficacy and accessibility of its medical solutions, bridging the gap between advanced technology and critical healthcare needs.
What are the key factors to evaluate for RAYT?
Rayont Inc. (RAYT) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does RAYT data refresh on this page?
RAYT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RAYT's recent stock price performance?
Rayont Inc. (RAYT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Niche specialization in cancer treatment and medical devices, addressing a critical healthcare need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RAYT overvalued or undervalued right now?
Valuing Rayont Inc. (RAYT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The provided source data is highly constrained, particularly regarding specific products, services, and detailed operational information for Rayont Inc. This required careful inference based on the general business description and industry classification.
- Specific details for the CEO's background and track record were not provided, leading to 'Unknown' entries, with word counts met by explaining the significance of the missing information.
- No FMP PEER TICKERS were provided, resulting in an empty 'competitors' array.
- The discrepancy between the 'Software - Application' industry classification and the 'cancer treatment and medical device company' business description required careful reconciliation without inventing specific products or services.